BioSpace News Archive

BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Barclays Global Healthcare Conference in Miami Beach, Florida on Tuesday, March 10, 2020 at 8:00 a.m. ET.

Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced that it has expanded its Executive Team with the appointment of Chad A. Zaring to the newly-created role of Chief Commercial Officer (“CCO”), effective February 10, 2020.

Microbot Medical Inc. (NASDAQ: MBOT), announced the appointment of Eyal Morag, M.D., a leading radiologist, to Chief Medical Officer, effective immediately. In his new role, Dr. Morag will lead the development and execution of the clinical strategy of the Company’s technology platforms, including its current development of the Self-Cleaning Shunt (SCS) and LIBERTY products as well as its future pipeline.

Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”) today reported operating and financial results for the fourth quarter and full year ended December 31, 2019. The Company reported total revenue of $37.8 million for the fourth quarter of 2019 and $123.9 million for the year ended December 31, 2019.

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Tuesday, March 10, 2020 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the fourth quarter and year ended December 31, 2019.

Easterseals, the nation’s leading nonprofit service provider and advocate for the one in four people living with disability in America, recently elected Glenn Henderson, entrepreneur and motivational speaker, and Barry Simon, President and CEO at Easterseals of Oak Hill, to its National Board of Directors.

Eli Lilly and Company (NYSE: LLY) issued the following statement today regarding the novel coronavirus:

Neuraly, a clinical stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, today announced the dosing of the first patient in its Phase 2 clinical trial of NLY01 for Parkinson’s disease.

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will present an overview of the company’s business strategy and development-stage programs at the Barclays Global Healthcare Conference 2020 being held in Miami.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the European Commission (EC) has granted marketing authorization for GIVLAARI® (givosiran), an injection for subcutaneous use targeting aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyria (AHP) in adults and adolescents aged 12 years and older.